Study Condition(s): Ovarian Cancer, Advanced Cancer

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Study Alias: JTJN

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT03414047 {{ currentLocaleObject.registryAnchorText }}

Withdrawn Not yet recruiting

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with ovarian, primary peritoneal, or fallopian tube cancer that did not respond well to chemotherapy or has recurred.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Female

Age

18+ years

Time Commitment

Your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive. One cycle is 28 days.
  • Participants must have advanced ovarian, primary peritoneal or fallopian tube cancer
  • Participants must have cancer that did not respond well to chemotherapy and must have had the breast cancer gene test
  • Participants must have adequate organ function
  • Participants must be able and willing to undergo tumor biopsy before treatment
  • Participants must not have known central nervous system (CNS) cancer or cancer that has spread to the CNS
  • Participants must not have a history of any of the following:
    • Abdominal fistula (abnormal opening between the stomach or intestines and the skin) or gastrointestinal perforation (hole in the stomach or intestines)
    • Abdominal abscess (collection of fluid and puss inside the abdomen) within last 3 months
    • Bowel blockage within the last 3 months
  • Participants must not have symptoms of active HIV infection or hepatitis A, B, or C
  • Participants must not have a serious heart condition
  • Participants must not have received radiation to the whole pelvis
  • Participants must not take corticosteroids daily (with the exception of inhaled steroids)

Where to Participate

51 locations are currently available of 54 planned
Invalid Postal Code.
Please re-enter postal code.
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.